Gene · 3702
Papers2,789
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
501 to 520 of 2,789
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mining of transcriptome identifies CD109 and LRP12 as possible biomarkers and deregulation mechanism of T cell receptor pathway in Acute Myeloid Leukemia. | Heliyon | 2022 | 36299526 | PubTator, text mining | PubMed |
| Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux. | Pharmaceutics | 2022 | 36297430 | PubTator, text mining | PubMed |
| Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis. | J Clin Med | 2022 | 36294458 | PubTator, text mining | PubMed |
| NF-κB Mutations in Germinal Center B-Cell Lymphomas: Relation to NF-κB Function in Normal B Cells. | Biomedicines | 2022 | 36289712 | PubTator, text mining | PubMed |
| Identification of Key Genes in the HBV-Related HCC Immune Microenvironment Using Integrated Bioinformatics Analysis. | J Oncol | 2022 | 36281288 | PubTator, text mining | PubMed |
| Gene set-based identification of two immune subtypes of diffuse large B cell lymphoma for guiding immune checkpoint blocking therapy. | Front Genet | 2022 | 36276947 | PubTator, text mining | PubMed |
| TRAT1 overexpression delays cancer progression and is associated with immune infiltration in lung adenocarcinoma. | Front Oncol | 2022 | 36276113 | PubTator, text mining | PubMed |
| Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma. | Front Immunol | 2022 | 36275715 | PubTator, text mining | PubMed |
| Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo. | Technol Cancer Res Treat | 2022 | 36254554 | PubTator, text mining | PubMed |
| Small molecule inhibitors targeting the cancers. | MedComm (2020) | 2022 | 36254250 | PubTator, text mining | PubMed |
| Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma. | J Immunother Cancer | 2022 | 36252996 | PubTator, text mining | PubMed |
Protected biofactors and antioxidants reduce the negative consequences of virus and cold challenge while enhancing performance by modulating immunometabolism through cytoskeletal and immune signaling in the jejunum. | Poult Sci | 2022 | 36240637 | PubTator, text mining | PubMed |
| Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis. | Drug Des Devel Ther | 2022 | 36238195 | PubTator, text mining | PubMed |
| Bioinformatics and Experimental Analyses Reveal Immune-Related LncRNA-mRNA Pair AC011483.1-CCR7 as a Biomarker and Therapeutic Target for Ischemic Cardiomyopathy. | Int J Mol Sci | 2022 | 36233294 | PubTator, text mining | PubMed |
| Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing. | Cells | 2022 | 36230993 | PubTator, text mining | PubMed |
| Spatial Profiling of the Prostate Cancer Tumor Microenvironment Reveals Multiple Differences in Gene Expression and Correlation with Recurrence Risk. | Cancers (Basel) | 2022 | 36230846 | PubTator, text mining | PubMed |
| Identification of Immuno-Targeted Combination Therapies Using Explanatory Subgroup Discovery for Cancer Patients with EGFR Wild-Type Gene. | Cancers (Basel) | 2022 | 36230688 | PubTator, text mining | PubMed |
| Phosphoproteomic Analysis Identifies TYRO3 as a Mediator of Sunitinib Resistance in Metastatic Thymomas. | Cancers (Basel) | 2022 | 36230684 | PubTator, text mining | PubMed |
| [CD40LG is a novel immune- and stroma-related prognostic biomarker in the tumor microenvironment of invasive breast cancer]. | Nan Fang Yi Ke Da Xue Xue Bao | 2022 | 36210698 | PubTator, text mining | PubMed |
| Screening of Sepsis Biomarkers Based on Bioinformatics Data Analysis. | J Healthc Eng | 2022 | 36199375 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3702/papers?page=26